Greenwich LifeSciences, Inc. (GLSI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 16.57 |
| Open | 16.26 |
| Day High | 16.7 |
| Day Low | 15.21 |
| 52-Week High | 34.1 |
| 52-Week Low | 7.78 |
| Volume | 72,431 |
| Average Volume | 126,910 |
| Market Cap | 223.24M |
| PE | -11.61 |
| EPS | -1.31 |
| Moving Average 50 Days | 16.69 |
| Moving Average 200 Days | 21.83 |
| Change | -1.36 |
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01
GlobeNewswire Inc.
Mar 03, 2026 11:00 AM GMT
STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designa
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026
GlobeNewswire Inc.
Feb 24, 2026 11:00 AM GMT
STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designat
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
GlobeNewswire Inc.
Jan 27, 2026 11:00 AM GMT
STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designat